Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat in incipient pulmonary vascular disease (early pulmonary arterial hypertension)
2023-509695-42-00Phase 2Completed
- Sponsor
- Thoraxklinik am Universitätsklinikum Heidelberg
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in pulmonary vascular disease (PVD) and pulmonary arterial hypertension (PAH) comparing Riociguat with Placebo (2 arms). Primary endpoint: Pulmonary vascular resistance change. Started Nov 2024; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary vascular disease (PVD)pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2023-509695-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509695-42-00.